The therapeutic potential of natural anti-T-cell receptor (TCR) antibodies is largely unknown. We investigated whether passive administration of C1-19, a novel natural anti-TCRVβ8 monoclonal antibody, could interfere with the development of EAE. Treatment with C1-19 prevented myelin basic protein (MBP)-induced EAE in Vβ8-sufficient B10.PL but not in Vβ8-deficient SJL mice. Furthermore, C1-19 reduced disease severity when administrated shortly after disease onset. These protective effects of C1-19 correlated with a Th2 bias of the cytokine response, in the absence of T-cell deletion or anergy. Together, these findings indicate that natural anti-TCR antibodies could function as therapeutic tools in autoimmune inflammatory diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jneuroim.2011.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.
Eur J Neurol
November 2024
Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
Background And Purpose: Since its description by Guillain, Barré, and Strohl in 1916, Guillain-Barré syndrome (GBS) has attracted a large literature. The author reviews the history of research into its pathogenesis and treatment to highlight promising avenues for future research.
Methods: This is a nonsystematic personal review.
Genetic code expansion in E. coli enables production of a functional 'ready-to-click' T cell receptor-specific scFv.
N Biotechnol
September 2023
acib - Austrian Centre of Industrial Biotechnology, Petersgasse 14, 8010 Graz, Austria; Institute of Molecular Biotechnology, Graz University of Technology, Petersgasse 14, 8010 Graz, Austria; Institute of Bioprocess Science and Engineering, Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria. Electronic address:
Article Synopsis
- Antibody-based cancer therapies, particularly bispecific antibody-drug conjugates, are advancing quickly in the pharmaceutical industry, enhancing immunotherapy's effectiveness.
- Miniaturized antibody fragments like diabodies, nanobodies, and scFvs show great potential for targeting and penetrating tumor tissues in cancer treatments.
- This study developed a versatile scFv OKT3 antibody using E. coli, incorporating a unique amino acid for efficient 'click chemistry' conjugation, intending for applications in controlled anti-T cell therapies and cancer imaging.
TIGIT blockade repolarizes AML-associated TIGIT M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
J Immunother Cancer
December 2022
Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Leukemia-associated macrophages (LAMs) represent an important cell population within the tumor microenvironment, but little is known about the phenotype, function, and plasticity of these cells. The present study provides an extensive characterization of macrophages in patients with acute myeloid leukemia (AML).
Methods: The phenotype and expression of coregulatory markers were assessed on bone marrow (BM)-derived LAM populations, using multiparametric flow cytometry.
Comparison of immune reconstitution between anti-T-lymphocyte globulin and posttransplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation.
Haematologica
April 2022
Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg.
Anti-T-cell lymphocyte globulin (ATLG) and posttransplant cyclophosphamide (PTCy) are now widely used strategies to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation. Data comparing immune reconstitution (IR) between ATLG and PTCy is scarce. This retrospective study conducted at the University Medical Center Hamburg-Eppendorf (UKE) compares PTCy (n=123) and ATLG (n=476) after myeloablative allogeneic peripheral blood stem cell transplant.
View Article and Find Full Text PDFTargeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis.
Blood Adv
May 2020
Department of Immunology. Hematology, Oncology and SCT, University Children's Hospital, Zurich, Switzerland.
Reduced-intensity/reduced-toxicity conditioning and allogeneic T-cell replete hematopoietic stem cell transplantation are curative in patients with hemophagocytic lymphohistiocytosis (HLH). Unstable donor chimerism (DC) and relapses are clinical challenges . We examined the effect of a reduced-intensity conditioning regimen based on targeted busulfan to enhance myeloid DC in HLH.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!